Начало・Списък с акции・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Затворен

СекторЗдравеопазване

10.69 -3.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.63

Максимум

10.75

Ключови измерители
By Trading Economics
Приходи	106M -96M
Продажби	-8M 15M
EPS	-0.81
Марж на печалбата	-639.494
Служители	377
EBITDA	1.4M -94M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+77.15% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-159M 1.5B
Предишно отваряне	14.3
Предишно затваряне	10.69

Настроения в новините

By Acuity

18%

82%

28 / 340 Класиране в Healthcare

Intellia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2026 г., 20:06 ч. UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30.07.2026 г., 17:57 ч. UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29.07.2026 г., 23:31 ч. UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28.07.2026 г., 18:36 ч. UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27.07.2026 г., 23:46 ч. UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25.07.2026 г., 00:02 ч. UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24.07.2026 г., 13:31 ч. UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23.07.2026 г., 19:16 ч. UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22.07.2026 г., 23:56 ч. UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

21.07.2026 г., 22:46 ч. UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

20.07.2026 г., 23:41 ч. UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Сравнение с други в отрасъла

Ценова промяна

Intellia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

77.15% нагоре

12-месечна прогноза

Среден 18.92 USD 77.15%

Висок 49 USD

Нисък 8 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Intellia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Intellia Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

28 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.